N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE

Description

H-89 (127243-85-0) is a commonly used inhibitor of protein kinase A (PKA? IC50?= 140 nM).? Inhibits a variety of other kinases including S6K1 (IC50?= 80 nM), MSK1 (120 nM), ROCK II (270 nM), PKBα (2.6 μM), PKD, PRK2, RSK1 and 2, SGK, AMPK, CHK1 and MAPKAP-K1b (2.8 μM).1,2

Chemical properties

White Solid

The Uses of N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE

Selective inhibitor of Protein Kinase A (cyclic AMP-dependeant Protein Kinase) with an inhibitory constant of 0.0048 uM

The Uses of N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE

Selective inhibitor of Protein Kinase A (cyclic AMP-dependeant Protein Kinase) with an inhibitory constant of 0.0048 uM.

Definition

ChEBI: A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N1-[3-(4-bromophenyl)prop-2-en-1-yl]et ane-1,2-diamine.

General Description

A cell-permeable, selective, reversible, ATP-competitive and potent inhibitor of protein kinase A (K_i = 48 nM). Inhibits other kinases at several fold higher concentrations: myosin light chain kinase (K_i = 28.3 μM), Ca²⁺/calmodulin-dependent protein kinase II (K_i = 29.7 μM), protein kinase C (K_i = 31.7 μM), casein kinase I (K_i = 38.3 μM), and Rho Kinase II (IC₅₀ = 270 nM). May be used to discriminate between the effects of PKA and cAMP-regulated guanine-nucleotide-exchange factors (GEFs), such as GEFI or Epac (exchange protein directly activated by cAMP) and GEFII. Reported to induce neurite formation in NG 108-15 cells (~1 mM) by blocking the action of Rho kinase II.

Biological Activity

Protein kinase A inhibitor that also inhibits several other kinases (IC 50 values are 80, 120, 135, 270, 2600 and 2800 nM for S6K1, MSK1, PKA, ROCKII, PKB α and MAPKAP-K1b).

Biochem/physiol Actions

Target Ki: 48 nM for protein kinase A

References

1) Lochner and Moolman (2006),?The many faces of H89: a review; Cardiovasc. Drugs,?24?261 2) Bain?et al. (2007),?The selectivity of protein kinase inhibitors: a further update; Biochem.J.?408(Pt3)?297